Vitamin D in Morocco: Sun D3, Devit-3 supplementation 2026

01The Moroccan paradox: a sun-soaked nation with severe vitamin D deficiency#

Morocco enjoys an annual average of 2,800 to 3,000 hours of sunshine across the entire territory, one of the highest figures in the Mediterranean basin. Yet several Moroccan hospital studies conducted between 2018 and 2024 (CHU Ibn Sina in Rabat, CHU Mohammed VI in Marrakech, CHU Ibn Rochd in Casablanca) converge on a striking conclusion: between 60 and 90 % of the Moroccan population show a deficit in vitamin D, defined by a serum 25-hydroxyvitamin D (25-OH-D) level below 30 ng/mL.

Vitamin D is, first and foremost, a prohormone synthesised by the skin when exposed to UVB radiation (wavelength 290-315 nm). Once produced in the skin or ingested as cholecalciferol (D3, animal origin) or ergocalciferol (D2, plant origin), it undergoes two successive hydroxylations — first hepatic, then renal — to become active calcitriol. This active hormone regulates intestinal absorption of calcium and phosphorus, bone mineralisation, immune function and muscle performance, in addition to playing multiple roles in inflammation control and cellular differentiation.

The national list of reimbursable medicines (LMR) issued by the ANAM (Agence Nationale de l'Assurance Maladie) includes Sun D3 and Devit-3 as core preventive and curative supplements.

02Morocco-specific causes#

Behavioural and cultural factors: clothing coverage (long djellaba, hijab, niqab) limits skin exposure. A Moroccan study published in 2019 in Pan African Medical Journal on veiled versus unveiled women in Fes and Marrakech reported 25-OH-D levels of 11 to 12 ng/mL among veiled women compared with 18 to 19 ng/mL among unveiled women of the same age and social class.

Urban lifestyle: 10 or more hours per day spent indoors in homes, offices and schools. Between November and February, the solar incidence angle before 10 a.m. and after 4 p.m. makes cutaneous vitamin D production negligible, even with direct exposure.

Melanin: individuals with phototypes III to V require 3 to 5 times longer exposure to produce the same amount of vitamin D (Clemens 1982, Webb 2018). Atmospheric pollution in large cities blocks part of the UVB radiation. High-SPF sunscreens almost completely halt cutaneous production. Obesity (affecting around 20 % of Moroccan adults according to the national STEPS 2017-2018 survey) sequesters vitamin D in adipose tissue, reducing its bioavailability.

0325-OH vitamin D testing#

The reference test measures total serum 25-hydroxyvitamin D. Internationally accepted classification: severe deficiency below 10 ng/mL, deficiency 10-20, insufficiency 20-30, optimal sufficiency 30-60, alert zone above 100 ng/mL.

Price in Morocco in 2026: between 180 and 320 dirhams (average 220 MAD in Rabat and Casablanca). Free in university hospitals but with waiting times of three weeks or more. CNSS and CNOPS reimburse partially on medical prescription.

Testing is not mandatory before starting supplementation: in infants, children, pregnant women and the elderly, the Moroccan Ministry of Health recommends systematic preventive supplementation without prior testing.

04Sun D3 drops: the Moroccan paediatric reference#

Sun D3 oral solution drops comes in a 10 ml dropper bottle delivering 200 IU per drop according to the package leaflet (approximately 10,000 IU/mL). The exact dose printed on each batch must be verified, as concentration may vary slightly between production runs.

Recommendations from the Moroccan Paediatric Society (SMP), aligned with HAS (France), SFP and AAP (US):

• Breastfed infant: 800-1,000 IU/day from the first week of life until 18 months (4-5 drops).
• Formula-fed infant on fortified milk: 400-800 IU/day (2-4 drops).
• Child 18 months-5 years: 600-800 IU/day from October to March.
• Child 5-12 years: 400-800 IU/day year-round in the presence of risk factors.
• Adolescent and adult under 70: 800-1,000 IU/day preventive, 1,500-2,000 IU in case of insufficiency.
• Over 70: 1,000-1,500 IU/day minimum (cutaneous synthesis falls by 75 %).

Neutral taste, oil-based vehicle. The product remains stable for two months after the bottle is opened. Price: 30-45 dirhams for the 10 ml bottle in 2026.

05Quarterly ampoules versus daily intake#

In Morocco the main forms are Devit-3 (100,000 or 200,000 IU) and Zentridol from Zenith Pharma at the same dosages. 600,000 IU ampoules (Uvedose in France) are not common in Morocco.

Recent meta-analyses (BMJ 2014, Lancet Diabetes & Endocrinology 2017) have shown that daily or weekly low-dose supplementation is more effective than monthly or quarterly high-dose boluses. 600,000 IU boluses are now discouraged by the French HAS.

SMEDIAN (Moroccan Society of Endocrinology, Diabetes and Nutrition) has favoured daily schemes since 2022 in children, pregnant women and the elderly.

Curative scheme for insufficiency 10-20 ng/mL (GRIO France): 80,000 IU every 15 days for 6 weeks (three ampoules), followed by maintenance of 1,000-1,500 IU/day. Severe deficiency below 10 ng/mL: 4 ampoules of 100,000 IU, each 15 days apart.

Pregnant women: 80,000-100,000 IU at the end of the 6th or beginning of the 7th month (26-28 weeks of amenorrhoea), followed by 400-800 IU/day during the last trimester.

06Pregnancy and breastfeeding#

Vitamin D deficiency during pregnancy increases the risk of pre-eclampsia, gestational diabetes, preterm delivery before 37 weeks, and low birth weight. In the newborn: neonatal rickets, disrupted early immune programming, delayed motor development.

Official protocol of the Moroccan Ministry of Health since 2021: 100,000 IU as a single oral dose between 26 and 28 weeks of amenorrhoea, complemented by 400-800 IU/day in women with risk factors (veiled, obese, dark phototype, winter, multiparity).

Breastfeeding: breast milk contains only 20-60 IU per litre, or about one tenth of the infant's daily requirement. The standard WHO/SFP strategy is to supplement the infant directly with Sun D3 from the first week of life. The alternative Hollis-Wagner strategy (Pediatrics 2015) recommends 6,400 IU/day to the breastfeeding mother to achieve adequate milk levels — off-label in Morocco and not to be initiated without specialist advice.

07Contraindications and drug interactions#

Absolute contraindications: hypercalcaemia, hypercalciuria, recurrent calcium kidney stones, sarcoidosis and granulomatous diseases (including tuberculosis), untreated primary hyperparathyroidism, severe renal impairment (eGFR below 30 mL/min), and hypersensitivity to any component.

Drug interactions: thiazide diuretics (hydrochlorothiazide, indapamide) potentiate the risk of hypercalcaemia. Digitalis glycosides become more arrhythmogenic. Corticosteroids, enzyme-inducing antiepileptics (carbamazepine, phenobarbital, phenytoin) and isoniazid accelerate vitamin D catabolism. Orlistat, cholestyramine and oily laxatives reduce absorption (space doses 2 to 4 hours apart).

In severe renal impairment (eGFR below 30): use calcitriol (Rocaltrol) or alfacalcidol (Un-Alfa) prescribed by a nephrologist, because the kidney can no longer activate standard vitamin D.

08Overdose and hypercalcaemia#

Vitamin D is fat-soluble and accumulates in adipose tissue and the liver. Upper safe limits according to EFSA 2023: 4,000 IU/day for adults and adolescents, 2,000 IU/day for children aged 1-10, 1,000 IU/day for infants. Sustained intake above 10,000 IU/day significantly raises the risk of hypercalcaemia.

Hypercalcaemia (corrected serum calcium above 2.6 mmol/L) presents with: intense thirst and polyuria, constipation, nausea and loss of appetite, cognitive fatigue and confusion. Severe forms: nephrocalcinosis, kidney stones, cardiac rhythm disturbances that may progress to cardiac arrest.

Clinical management: immediate cessation of all calcium and vitamin D supplements, intravenous saline 0.9 % hyperhydration at 3-4 L/24 h in adults, furosemide after volume restoration, IV bisphosphonates (pamidronate, zoledronate) in severe forms, corticosteroids (prednisone 20-40 mg/day), and calcitonin in exceptional cases.

09Foods rich in vitamin D#

Oily fish: sardine 200-300 IU/100 g, mackerel 400-600, salmon 500-800, canned tuna 200-250. Cod liver oil: up to 10,000 IU per tablespoon. Eggs: 40 IU per yolk. UV-exposed mushrooms (oyster, shiitake): up to 1,000 IU/100 g.

A balanced diet provides at best 200-400 IU/day, roughly half the minimum requirement. Supplementation therefore remains essential for at-risk groups.

10Prices and reimbursement#

Sun D3: 30-45 MAD per bottle in 2026. Devit-3: 15-35 MAD per ampoule. Zentridol: 20-45 MAD. A complete annual adult course costs 120-250 MAD per year.

Listed on the national reimbursable medicines list LMR ANAM: AMO CNSS reimburses retail purchases at 70 % of the reference tariff (90-100 % under ALD long-term condition status), CNOPS at 80 % (100 % ALD). AMO TADAMON (which replaced RAMED in 2022-2024) opens free access in public health centres.

11Paediatric rickets: still present in Morocco#

Rickets caused by vitamin D deficiency is not a museum disease: paediatric departments at Moroccan university hospitals (Ibn Sina, Ibn Rochd, Mohammed VI) still report cases, particularly in exclusively breastfed infants without systematic supplementation, in disadvantaged settings or geographically isolated rural families. The clinical picture: craniotabes (palpable softening of the cranial vault), rachitic rosary (chondrocostal swelling), enlargement of wrists and ankles, bowing of the long bones (genu varum, genu valgum), stunted growth, delayed walking beyond 18 months, axial hypotonia, and in young infants hypocalcaemic seizures.

Biological diagnosis rests on 25-OH-D below 10 ng/mL, elevated bone alkaline phosphatase, hypocalcaemia or hypophosphataemia, secondary hyperparathyroidism, and typical radiographic findings (widened growth plates, cupping, delayed ossification). Curative treatment proceeds in two stages: a loading dose of 100,000 to 200,000 IU orally under medical supervision, followed by 1,000 to 2,000 IU/day for 3 to 6 months until bone parameters and 25-OH-D normalise. Oral calcium supplementation 50 mg/kg/day is added in young children.

Systematic prevention in breastfed infants relies on Sun D3 oral solution drops from the first week of life: 800 to 1,000 IU/day until 18 months, i.e. 4-5 drops daily. Outreach work remains needed in some rural Moroccan areas where systematic paediatric supplementation reaches only 60-70 % of infants according to the PAPFAM 2018-2019 national survey.

12Veiled women, returning MREs, elderly women: three key profiles#

The veiled Moroccan woman represents the highest documented deficiency risk profile in the medical literature: near-permanent outdoor clothing coverage, phototype III-V skin requiring prolonged exposure, and reduced exposure time confined to short urban commutes. The 2019 Pan African Medical Journal study reported 11-12 ng/mL in veiled women in Fes and Marrakech versus 18-19 ng/mL in unveiled women of the same cohort. Systematic preventive supplementation at 800-1,000 IU/day is justified in every veiled woman of reproductive age, with reinforcement during pregnancy and lactation.

The Moroccan MRE woman returning to Morocco after several years in Northern Europe (Belgium, Netherlands, Germany, United Kingdom, Sweden) combines two risk factors: an intermediate phototype poorly adapted to northern latitudes (minimal cutaneous production for 6 months of the year) and prolonged winter clothing habits. A 25-OH-D test on arrival in Morocco is recommended to adjust supplementation, which may require a curative initial scheme (80,000 IU every 15 days for 6 weeks) followed by daily maintenance.

The elderly Moroccan woman over 70 has a 75 % reduction in cutaneous synthesis and reduced intestinal absorption, often in a context of post-menopausal osteopenia or osteoporosis. Supplementation at 1,000-1,500 IU/day is associated with a 15-20 % reduction in falls and hip fractures, particularly when combined with 1,000-1,200 mg/day of calcium (Bischoff-Ferrari meta-analysis, NEJM 2012). Controversy persists — the VITAL trial (2018) did not confirm anti-fracture benefits in the non-deficient general population. Current HAS and SMEDIAN position: maintain supplementation in the frail elderly at risk of falls.

13Vitamin D and pregnancy: detailed protocol#

Vitamin D deficiency during pregnancy in Morocco affects 70 to 85 % of women according to the prospective study at CHU Hassan II in Fes (2019), with documented increased risk of pre-eclampsia (BMJ 2017 meta-analysis, OR 1.71 if 25-OH-D below 20 ng/mL), gestational diabetes (OR 1.38, Diabetologia 2018), preterm delivery and low birth weight. Prevention follows the Moroccan Ministry of Health 2021 protocol: 100,000 IU as a single oral dose between 26 and 28 weeks of amenorrhoea, plus 400-800 IU/day during the third trimester in women with risk factors.

Breastfeeding covers only 20-60 IU/L, less than 10 % of the infant's daily needs. Two strategies coexist: direct infant supplementation with Sun D3 from the first week (the WHO, SFP and AAP strategy recommended in Morocco), or high-dose supplementation of the breastfeeding mother at 6,400 IU/day to achieve adequate milk levels (Hollis Pediatrics 2015 — off-label in Morocco, not to be initiated without specialist advice).

Maternal vitamin D during pregnancy is associated with better fetal bone development, in utero cranial growth and improved infant immune parameters (Lancet 2019 meta-analysis). Conversely, maternal excess above 4,000 IU/day provides no additional benefit and may expose the mother to hypercalcaemia.

14The full biochemical pathway: from skin to gene#

It is worth understanding precisely how a simple cholesterol-derived molecule in the epidermis ends up acting on nuclear DNA. The chain begins with 7-dehydrocholesterol, present in epidermal keratinocytes. Under UVB radiation of wavelength 290 to 315 nm, this precursor undergoes photochemical ring opening to form previtamin D3, which is then progressively thermally isomerised into cholecalciferol (vitamin D3). The molecule is transported in the bloodstream bound to a specific carrier protein, vitamin D-binding protein (DBP), towards the liver.

In hepatocytes, cholecalciferol undergoes the first hydroxylation through the enzyme CYP2R1 (25-hydroxylase), producing 25-hydroxyvitamin D (25-OH-D). This is the circulating form measured in clinical practice to assess a patient's vitamin D status. 25-OH-D has no intrinsic hormonal activity but functions as a body reserve (half-life roughly three weeks), which explains why occasional high-dose ampoules can theoretically sustain measurable levels for several weeks.

25-OH-D then travels to the kidney, where CYP27B1 (1-alpha-hydroxylase) adds a second hydroxyl group to generate calcitriol (1,25-dihydroxyvitamin D), the biologically active hormonal form. This renal conversion is tightly regulated by parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), and serum calcium and phosphate levels. CYP27B1 is also expressed in extra-renal tissues — macrophages, placental trophoblasts, prostate epithelial cells, keratinocytes — which explains the autocrine and paracrine roles of vitamin D in immunity, the placental interface and the skin.

Calcitriol acts through the vitamin D nuclear receptor (VDR), expressed in more than 35 human tissue types. Once bound, VDR forms a heterodimer with the retinoid X receptor (RXR), and this complex docks onto vitamin D response elements (VDRE) located in the regulatory regions of more than 1,000 human genes, either activating or repressing transcription. This sweeping genomic influence is the reason any complex therapeutic intervention should be preceded by correction of an underlying vitamin D deficit, and also explains why the clinical response to supplementation takes weeks to months before its full effect is visible.

15Vitamin D and extra-skeletal health: what the 2026 literature shows#

Vitamin D has long outgrown its classical role in phospho-calcium metabolism and is now studied across several medical specialties, with levels of evidence that vary and should invite caution. On the cardiovascular front, observational studies have consistently shown an inverse association between 25-OH-D levels and the risk of myocardial infarction, stroke and arterial hypertension. However, the major randomised controlled trials — chief among them the VITAL trial published in the New England Journal of Medicine in 2018 (25,871 participants, 5 years of follow-up on 2,000 IU/day of cholecalciferol) — have not confirmed a meaningful cardiovascular benefit in subjects who were not severely deficient. The current position of the American Heart Association and the European Society of Cardiology is therefore to correct deficiency without claiming to prevent cardiovascular events through isolated supplementation.

On the metabolic front, vitamin D deficiency is statistically associated with reduced insulin sensitivity and an increased risk of type 2 diabetes. The D2d trial (NEJM 2019, 2,423 pre-diabetic adults given 4,000 IU/day for 2.5 years) showed a 12 % reduction in diabetes incidence (not significant in intention-to-treat analysis, but significant in subjects whose 25-OH-D remained below 12 ng/mL). In Morocco, where the prevalence of type 2 diabetes reaches 12.4 % in adults according to the national STEPS 2017-2018 survey, systematic correction of vitamin D deficiency in at-risk groups (overweight, family history, women with previous gestational diabetes) is part of the pragmatic recommendations of SMEDIAN (Moroccan Society of Endocrinology, Diabetes and Nutrition), even though the individual preventive effect remains modest.

On the immune and infectious front, the meta-analysis by Martineau (BMJ 2017, 25 trials, 11,321 participants) reported a 12 % reduction in the risk of acute respiratory infection under vitamin D supplementation, with a stronger effect in severely deficient subjects (below 10 ng/mL). During the COVID-19 pandemic, several Moroccan studies (CHU Ibn Sina, CHU Mohammed VI) confirmed that low 25-OH-D was associated with more severe disease, although curative supplementation in the acute phase did not yield demonstrable benefit. The position of the WHO and the French HAS is now clear: vitamin D is neither a treatment nor a vaccine, but correction of an established deficiency remains one of the cornerstones of immune health.

On the front of depression and mental health, the statistical link with seasonal affective disorder (SAD) and major depression is documented, particularly in Nordic countries. In Morocco the topic is under-studied but clinically relevant in sedentary veiled women in winter, in whom severe deficiency may accompany diffuse asthenia, sleep disturbance and depressive mood — symptoms that can partially regress with supplementation.

On the muscular and falls-prevention front, the effect is by contrast solid and reproducible: the Bischoff-Ferrari meta-analysis (BMJ 2009, updated 2012) showed a 15 to 20 % reduction in the risk of falls in elderly subjects taking 700 to 1,000 IU/day. On this indication, systematic supplementation of the frail elderly retains its standing as a cost-effective public health measure and underpins the Moroccan national protocols for the prevention of osteoporosis and hip fracture.

16A practical algorithm for screening and management in primary care#

For the Moroccan general practitioner, paediatrician or gynaecologist who wishes to integrate vitamin D management into daily practice without unnecessarily inflating the prescription, the following synthetic algorithm aligns with SMEDIAN, SMP and Moroccan Ministry of Health recommendations for 2021-2024.

Step 1 — Identify groups to supplement without testing: every infant from birth to 18 months (Sun D3 800-1,000 IU/day), every child from 18 months to 5 years during the winter period (600-800 IU/day from October to March), every pregnant woman in the third trimester (400-800 IU/day plus a 100,000 IU ampoule at 26-28 weeks of amenorrhoea), every person over 70 (1,000-1,500 IU/day year-round), and every veiled woman of reproductive age (800-1,000 IU/day). In these five groups, prior testing is neither necessary nor recommended: the preventive benefit-risk balance is already established and does not warrant a laboratory work-up that would weigh on the patient's wallet.

Step 2 — Test 25-OH-D in targeted indications: clinical suspicion of symptomatic deficiency (diffuse bone pain, unexplained muscle weakness, repeated falls in the elderly), confirmed osteoporosis or osteomalacia, inflammatory bowel disease (Crohn's, ulcerative colitis), bariatric surgery, chronic renal impairment, hepatic insufficiency, chronic treatment with corticosteroids, enzyme-inducing antiepileptics, antiretrovirals or orlistat, and documented malabsorption (coeliac disease, cystic fibrosis, chronic pancreatitis). The result drives the therapeutic scheme: sufficiency above 30 ng/mL (continue prevention at 800-1,000 IU/day), insufficiency 20-30 ng/mL (1,500-2,000 IU/day for 3 months then prevention), deficiency 10-20 ng/mL (GRIO curative scheme — 80,000 IU every 15 days for 6 weeks), severe deficiency below 10 ng/mL (4 ampoules of 100,000 IU each 15 days apart).

Step 3 — Re-test after 3 months only in indications that warranted initial testing, to confirm normalisation and adjust the maintenance dose. Thereafter, an annual check suffices in at-risk patients (chronic renal impairment, malabsorption, long-term medication).

Step 4 — Adapt to the cultural and socio-economic profile: the prescription should always be accompanied by brief therapeutic education: explain why Moroccan sunshine, abundant as it is, does not suffice; remind the patient that vitamin D is fat-soluble (to be taken with a meal containing some fat to optimise absorption); insist on daily compliance rather than monthly or quarterly boluses; and quote the real annual cost (120 to 250 MAD per year) to remove economic reluctance in lower-income groups. In practice, a clear written prescription that names the product, the dose, the daily timing and the duration of treatment achieves adherence rates of 75-80 % at six months, against only 30-40 % for a purely oral instruction.

17Sport, physical activity and muscle performance#

Vitamin D plays a structural and functional role in skeletal muscle through the VDR receptor expressed in muscle fibres. A sustained severe deficit translates clinically into proximal myopathy (weakness of the limb girdles, difficulty rising from a chair, waddling gait), reduced isometric strength and prolonged recovery time after exertion. In amateur and competitive athletes, several studies — notably a 2022 pilot study on professional footballers in the Moroccan Botola championship — have reported mean 25-OH-D levels of 18 to 22 ng/mL during the winter season, below the 30 ng/mL threshold associated with optimal muscular performance.

Sport-medicine recommendations converge on a target of 25-OH-D at or above 40 ng/mL in high-level athletes, achieved through daily supplementation of 2,000 to 4,000 IU/day (never exceeding the EFSA upper limit of 4,000 IU/day without biological monitoring). The documented effects concern a reduction in stress-fracture risk (Sports Medicine 2018 meta-analysis), a lower incidence of upper respiratory infections in the cold season, and a marginal effect on maximal strength parameters. There is, however, no evidence of an ergogenic effect in non-deficient athletes: supplementation beyond physiological needs does not increase VO₂max or aerobic performance.

In practical terms, Moroccan professional athletes should be tested for 25-OH-D at the start of the season (September-October), started on a preventive 2,000 IU/day supplement throughout the winter, retested after 3 months to confirm that 40 ng/mL has been reached, and have the dose adjusted accordingly. For amateur athletes who train regularly (at least three weekly sessions) in indoor settings (gymnasium, fitness centre), the same principles apply at lower doses (1,000-2,000 IU/day).

18Calcium, vitamin D and magnesium synergy#

The efficacy of vitamin D supplementation is tightly dependent on calcium and magnesium status, both of which act as indispensable cofactors for the two metabolic hydroxylations (hepatic CYP2R1 and renal CYP27B1). In Morocco, mean adult dietary calcium intake is estimated at 600-750 mg/day, well below the WHO recommendation of 1,000-1,200 mg/day, owing to moderate dairy consumption and a high share of refined white bread in the diet. The main calcium sources in the Moroccan kitchen include: milk (120 mg/100 mL), fresh local cheese (jbena beldia) (150-300 mg/100 g), fermented milk (rayeb) (130 mg/100 g), canned sardines (300-400 mg/100 g thanks to the small edible bones), and dark leafy greens such as spinach, parsley and turnip greens in modest amounts (50-150 mg/100 g).

This relative calcium shortfall justifies, in the osteoporotic elderly, the systematic pairing of calcium 1,000-1,200 mg/day with vitamin D 800-1,000 IU/day, which lowers the risk of hip fracture by 15 to 20 % (Bischoff-Ferrari NEJM 2012 meta-analysis). The daily calcium dose should be split into two or three intakes (intestinal absorption saturates around 500 mg per dose), and intake above 1,500 mg/day should be avoided because of a small associated increase in cardiovascular events.

Magnesium, an often-overlooked enzymatic cofactor, is also frequently deficient in Morocco (STEPS 2017-2018: 30 to 40 % of intakes below dietary recommendations). Magnesium deficiency can induce resistance to vitamin D supplementation: despite correct daily cholecalciferol intake, 25-OH-D levels struggle to rise above 20 ng/mL because the hydroxylating enzymes require magnesium to function. Correction with 300-400 mg/day of oral magnesium (preferably as bisglycinate or citrate, which are better absorbed and better tolerated digestively than the oxide form) typically unblocks the situation and allows 25-OH-D to climb to physiological levels. In patients who appear refractory to vitamin D supplementation despite good adherence, measuring erythrocyte magnesium or empirically adding magnesium has become a pragmatic everyday recommendation.

Moroccan dietary sources of magnesium include: almonds and nuts (270 mg/100 g in almonds), dark chocolate 70 % or higher (228 mg/100 g), whole grains (oats, bulgur, wholemeal bread), pulses (lentils, chickpeas, broad beans), and green tea leaves, which are consumed daily across Morocco and contribute a moderate but cumulatively meaningful intake.

19In summary#

Vitamin D supplementation is one of the simplest, most effective and most cost-efficient public health interventions available in Morocco. Modern schemes favour daily low-dose intake over annual boluses. Sun D3 remains the paediatric reference thanks to its precise dropper bottle. Systematic supplementation in breastfed infants, pregnant women, veiled women of reproductive age, and the frail elderly constitutes the foundation of an effective bone and immune prevention policy at negligible cost (120-250 MAD per patient per year).

Medical disclaimer. This information is provided for educational purposes and does not replace a medical consultation, paediatric opinion or personalised pharmaceutical advice. Any prolonged supplementation, and especially any high-dose prescription, must be validated by your doctor, paediatrician or pharmacist. If symptoms of hypercalcaemia appear (intense thirst, polyuria, nausea, fatigue, confusion), stop supplementation immediately and seek medical advice.